Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man.
Authors:
- A D'AzzoADA D'Azzo
- A HoogeveenAHA Hoogeveen
- A J ReuserARA J Reuser
- D RobinsonDRD Robinson
- H GaljaardHGH Galjaard
- 1 August 1982
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 79 (15) , 4535-4539
Abstract
In normal human fibroblasts, an enzymically active 85,000-dalton precursor form of beta-galactosidase is processed, via a number of intermediates, into a mature 64,000-dalton form. In addition there is an enzymically inactive 32,000-dalton component and its 54,000-dalton precursor. In fibroblasts from patients with a combined deficiency of beta-galactosidase and neuraminidase these last two components are absent and hardly any mature beta-galactosidase can be demonstrated. Nevertheless, in the mutant fibroblasts, precursor beta-galactosidase is synthesized and processed normally. The excessive intralysosomal degradation that is responsible for the deficiency of mature beta-galactosidase can be partially corrected by addition of the protease inhibitor leupeptin, which results in the accumulation of 85,000-dalton precursor beta-galactosidase and of a partially processed 66,000-dalton form. When mutant cells were grown in the presence of a "corrective factor" purified from the medium of NH4Cl-stimulated cell cultures, both beta-galactosidase and neuraminidase activities were restored to low control levels. The immunoprecipitation pattern was completely normal after addition of the corrective factor, and mature 64,000-dalton beta-galactosidase accumulated in the mutant fibroblasts. We propose that the combined beta-galactosidase/neuraminidase deficiency is caused by a defective 32,000-dalton glycoprotein which is normally required to protect beta-galactosidase and neuraminidase against excessive intralysosomal degradation and to give these enzymes their full hydrolytic activity.Keywords
This publication has 24 references indexed in Scilit:
- Enhanced proteolytic degradation of normal β-galactosidase in the lysosomal storage disease with combined β-galactosidase and neuraminidase deficiencyBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1982
- Correction of combined β-galactosidase/neuraminidase deficiency in human fibroblastsBiochemical and Biophysical Research Communications, 1981
- Genetic heterogeneity in human neuraminidase deficiencyNature, 1980
- Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling.Journal of Cell Biology, 1980
- Prenatal diagnosis of sialidosis with combined neuraminidase and ø‐galactosidase deficiencyClinical Genetics, 1979
- Sialidase (α‐N‐acetyl neuraminidase) deficiency: the enzyme defect in an adult with macular cherry‐red spots and myoclonus without dementiaClinical Genetics, 1978
- Mucolipidosis I: Increased sialic acid content and deficiency of an α-N-acetylneuraminidase in cultured fibroblastsBiochemical and Biophysical Research Communications, 1977
- Increased levels of sialic acid associated with a sialidase deficiency in I-cell disease (mucolipidosis II) fibroblastsBiochemical and Biophysical Research Communications, 1976
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970
- Generalized Gangliosidosis: Beta-Galactosidase DeficiencyScience, 1968